Drug-induced liver injury: Summary of a single topic clinical research conference

Hepatology

Volumn 43, Issue 3, 2006, Pages 618-631

  Watkins, Paul B ^a,c   Seeff, Leonard B ^b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; CARBAMAZEPINE; CEPHALOSPORIN DERIVATIVE; CHLORPROMAZINE; COTRIMOXAZOLE; DIHYDRALAZINE; ERYTHROMYCIN; GENOMIC DNA; HALOPERIDOL; HALOTHANE; HYDRALAZINE; HYDRAZINE DERIVATIVE; MACROLIDE; METHYLDOPA; MINOCYCLINE; NITROFURANTOIN; ORAL CONTRACEPTIVE AGENT; OXYPHENISATINE; PARACETAMOL; PEMOLINE; PENICILLIN DERIVATIVE; PHENOBARBITAL; PHENYTOIN; SULFONAMIDE; TIENILIC ACID; TUBERCULOSTATIC AGENT; UNINDEXED DRUG; VALPROIC ACID;

CHOLESTATIC HEPATITIS; CLINICAL RESEARCH; DRUG INDUCED DISEASE; HEREDITY; HUMAN; LIVER INJURY; LIVER TOXICITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

ACETAMINOPHEN; ADULT; ANALGESICS; CHILD; GENETIC PREDISPOSITION TO DISEASE; GENOMICS; HEPATITIS, TOXIC; HIV INFECTIONS; HUMANS; IMMUNITY, NATURAL; LIVER DISEASES;

EID: 33645220583     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21095     Document Type: Review

References (109)

1. Temple R. Hepatotoxicity through the years: Impact on the FDA. Available at: http://www.fda.gov/cder/livertox/Presentations/im1389/sld013.htm.
2. Watkins PB. Idiosyncratic liver injury: challenges and approaches. Toxicol Pathol 2005;33:1-5.
3. Hoofnagle JH, Drug-induced liver injury network (DILIN). HEPATOLOGY 2004;40:773.
4. Danan G, Benichou C. Causality assessment of adverse reactions to drugs-I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993;46:1323-1330.
5. Meier Y, et al. Incidence of drug-induced liver injury in medical inpatients. Eur J Clin Pharmacol 2005;61:135-143.
6. Ibanez L, Perez E, Vidal X, Laporte JR, Group d'Estudi Multicenteric d'Hepatotoxicitat Aguda de Barcelona (GEMHAB). Prospective surveillance of acute serious liver disease unrelated to infectious, obstructive, or metabolic diseases: epidemiological and clinical features, and exposure to drugs. J Hepatol 2002;37:592-600.
7. Bjornsson E, Olsson R. Suspected drug-induced liver fatalities reported to the WHO database. Dig Liver Dis 2005;38:33-38.
8. Andrade RJ, Lucerna MI, Fernandez MC, Pelaez G, Pachkoria K, Garcia-Ruiz E, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005;129:512-521.
9. Bjornsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. HEPATOLOGY 2005;42:481-489.
10. Teoh N, Farrell GC. Liver disease due to drugs. In: Feldman M, Friedman LS, Sleisenger MH, eds. Gastrointestinal and Liver Disease. 8th edition. Philadelphia: Saunders. 2003:730-737.
11. Chitturi SF, Drug induced liver disease. In Schiff ER, Maddrey WC, eds. Diseases of the Liver. New York: Lippincott, Williams & Wilkins, 2006:1059-1127.
12. Strader DB, Seeff LB. Hepatotoxicity of herbal preparations. In: Boyer T, Wright TL. Hepatology: A Textbook of Liver Disease. 5th ed. Philadelphia: Elsevier Inc, 2006. In press.
13. Schiodt FV, Rochling FA, Casey DL, Lee WM. Acetaminophen toxicity in an urban county hospital. N Engl J Med 1997;337:1112-1117.
14. Ostapowicz G, Fontana RJ, Schiodt FV, Larson A, Davern TJ, Han SH, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002;137:947-954.
15. Lee WM. Drug-induced hepatotoxicity. N Engl J Med 2003;349:474-485.
16. Lee WM. Acetaminophen and the U.S. Acute Liver Failure Study Group: lowering the risks of hepatic failure. HEPATOLOGY 2004;40:6-9.
17. Larson AM, Polson J, Fontana RJ, Davern TJ, Lalani E, Hynana LS, et al. Acetaminophen-induced acute liver failure: Results of a United States multi-center, prospective study. HEPATOLOGY 2005;42:1364-72.
18. Davern TJ, James LP, Hinson JA, Polson J, Larson AM, Fontana RJ, et al. Measurement of serum acetaminophen-protein adducts in patients with acute liver failure. Gastroenterology 2006. In press.
19. Clarkson A, Choonara I. Surveillance for fatal suspected adverse drug reactions in the UK. Arch Dis Child 2002;87:462-466.
20. Mitchell AA, Lacouture PG, Sheehan JE, Kauffman RE, Shapiro S. Adverse drug reactions in children leading to hospital admission. Pediatrics 1988;82:24-29.
21. Ginsberg G, Hattis D, Sonawane B. Incorporating pharmacokinetic differences between children and adults in assessing children's risks to environmental toxicants. Toxicol Appl Pharmacol 2004;198:164-183.
22. Rieder MJ, Uetrecht J, Shear NH, Cannon M, Miller M, Spielberg SP. Diagnosis of sulfonamide hypersensitivity reactions by in-vitro "rechallenge" with hydroxylamine metabolites. Ann Intern Med 1989;110:286-289.
23. Knowles SR, Shapiro LE, Shear NH. Anticonvulsant hypersensitivity syndrome: incidence, prevention and management. Drug Saf 1999;21:489-4501.
24. Schwabe MJ, Dobyns WB, Burke B, Armstrong L. Valproate-induced liver failure in one of two siblings with Alpers disease. Pediatr Neurol 1997;16:337-343.
25. Caravati EM. Unintentional acetaminophen ingestion in children and the potential for hepatotoxicity. J Toxicol Clin Toxicol 2000;38:291-296.
26. Zimmerman H. Hepatotoxicity. Philadelphia: Lippincott, Williams & Williams, 1999.
27. Huang YS, Chem HD, Su WJ, Wu JC, Chang SC, Chiang CH, et al. Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. HEPATOLOGY 2003;37:924-930.
28. Miller JA, Sapp RW, Miller EC. The carcinogenic activities of certain halogen derivatives of 4-dimethylaminoazobenzene in the rat. Cancer Res 1949;9:652-660.
29. Jollow DJ, Mitchell JR, Potter WZ, Davis DL, Gillette JR, Brodie BB. Acetaminophen-induced hepatic necrosis. II. Role of covalent binding in vivo. J Pharmacol Exp Ther 1973;187:195-202.
30. Park, BK, Kitteringham NR, Maggs JL, Pirmohamed M, Williams RP. The role of metabolic activation in drug-induced hepatotoxicity. Annu Rev Pharmacol Toxicol 2005;45:177-202.
31. Walgren JL, Mitchell MD, Thompson DC. Role of metabolism in drug-induced idiosyncratic hepatotoxicity. Crit Rev Toxicol 2005;35:325-361.
32. Evans DC, Watt AP, Nicoll-Grifith DA, Baillie TA. Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem Res Toxicol 2004;17:3-16.
33. Liebler DC, Guengerich FP. Elucidating mechanisms of drug-induced toxicity. Nat Rev Drug Discov 2005;4:410-420.
34. Nelson SD. Mechanisms of acetaminophen-induced liver disease. In:. Kaplowitz N, DeLeve LD, eds. Drug-induced Liver Disease. New York: Marcel Dekker Inc., 2003:287-325.
35. Court MH, Duan SX, von Moltke LL, Greenblatt DJ, Patten CJ, Miners JO. Interindividual variability in acetaminophen glucuronidation by human liver microsomes: identification of relevant acetaminophen UDP-glucuronosyltransferase isoforms. J Pharmacol Exp Ther 2001;299:998-1006.
36. Reiter C, Weinshilboum R. Platelet phenol sulfotransferase activity: correlation with sulfate conjugation of acetaminophen. Clin Pharmacol Ther 1982;32:612-621.
37. Bock KW, Kohle C. Coordinate regulation of drug metabolism by xenobiotic nuclear receptors: UGTs acting together with CYPs and glucuronide transporters. Drug Metab Rev 2004;36:595-615.
38. Chan K, Han XD, Kan YW. An important function of Nrf2 in combating oxidative stress: detoxification of acetaminophen. Proc Natl Acad Sci U S A 2001;98:4611-4616.
39. Enomoto A, Itoh K, Nagayoshi E, Haruta J, Kimura T, O'Connor T, et al. High sensitivity of Nrf2 knockout mice to acetaminophen hepatotoxicity associated with decreased expression of ARE-regulated drug metabolizing enzymes and antioxidant genes. Toxicol Sci 2001;59:169-177.
40. de Morais SM, Uetrecht JP, Wells PG. Decreased glucuronidation and increased bioactivation of acetaminophen in Gilbert's syndrome. Gastroenterology 1992;102:577-586.
41. Luyendyk JP, Maddox JF, Cosma GN, Ganey PE, Cockerell GL, Roth RA. Ranitidine treatment during a modest inflammatory response precipitates idiosyncrasy-like liver injury in rats. J Pharmacol Exp Ther 2003;307:9-16.
42. Luyendyk JP, Maddox JF, Green CD, Ganey PE, Roth RA. Role of hepatic fibrin in idiosyncrasy-like liver injury from lipopolysaccharideranitidine coexposure in rats. HEPATOLOGY 2004;40:1342-1351.
43. Luyendyk, JP, Shaw PJ, Green CD, Maddox JF, Ganey PE, Roth RA. Coagulation-mediated hypoxia and neutrophil-dependent hepatic injury in rats given lipopolysaccharide and ranitidine. J Pharmacol Exp Ther 2005;314:1023-1031.
44. Luyendyk, JP, Mattes WB, Burgoon LD, Zacharewski TR, Maddox JF, Cosma GN, et al. Gene expression analysis points to hemostasis in livers of rats cotreated with lipopolysaccharide and ranitidine. Toxicol Sci 2004;80:203-213.
45. Ganey, PE, Luyendyk JP, Maddox JF, Roth RA. Adverse hepatic drug reactions: inflammatory episodes as consequence and contributor. Chem Biol Interact 2004;150:35-51.
46. Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov 2005;4:489-499.
47. Liu ZX, Govindarajan S, Kaplowitz N. Innate immune system plays a critical role in determining the progression and severity of acetaminophen hepatotoxicity. Gastroenterology 2004;127:1760-1774.
48. Ishida, Y, Kondo T, Ohshima T, Fujiwara H, Iwakura Y, Mukaida N. A pivotal involvement of IFN-gamma in the pathogenesis of acetaminophen-induced acute liver injury. FASEB J 2002;16:1227-1236.
49. Zhang, H, Cook J, Nickel J, Yu R, Stecker K, Myers K, et al. Reduction of liver Fas expression by an antisense oligonucleotide protects mice from fulminant hepatitis. Nat Biotechnol 2000;18:862-867.
50. Bourdi, M, Masubuchi Y, Reilly TP, Amouzadeh HR, Martin JL, George JW, et al. Protection against acetaminophen-induced liver injury and lethality by interleukin 10: role of inducible nitric oxide synthase. HEPATOLOGY 2002;35:289-298.
51. Masubuchi, Y, Bourdi M, Reilly TP, Graf ML, George JW, Pohl LR. Role of interleukin-6 in hepatic heat shock protein expression and protection against acetaminophen-induced liver disease. Biochem Biophys Res Commun 2003;304:207-212.
52. Mackey I. The immunological mediation of drug reactions affecting the liver. In: Farrell GC, ed. Drug-induced Liver Disease. Edinburgh, Scotland: Churchill Livingstone, 1994:413-430.
53. Siddiqui J, Abraham J, Alla V, Chalasani NP, Wu Hy, Bonkovsky HL. Autoimmune hepatitis induced by statins. Gastroenterology 2005;(4 Suppl 2):A171.
54. Graziadei IW, Obermoser GE, Sepp NT, Erhart KH, Vogel W. Drug-induced lupus-like syndrome associated with severe autoimmune hepatitis. Lupus 2003;12:409-412.
55. Pelli N, Setti M, Ceppa P, Toncini C, Indiveri F. Autoimmune hepatitis revealed by atorvastatin. Eur J Gastroenterol Hepatol 2003;15:921-924.
56. Wolters LM, Van Buuren HR. Rosuvastatin-associated hepatitis with autoimmune features. Eur J Gastroenterol Hepatol 2005;17:589-590.
57. Kravitt EL, Autoimmune hepatitis. In: Schiff ER, Maddrey WC, eds. Schiffs Diseases of the Liver. Philadelphia, PA: Lippincott Williams & Wilkins, 2003:1001-1018.
58. Dansette PM, Bonierbale E, Minoletti C, Beaune PH, Pessayre D, Mansuy D. Drug-induced immunotoxicity. Eur J Drug Metab Pharmacokinet 1998;23:443-451.
59. Velayudham LS, Farrell GC. Drug-induced cholestasis. Expert Opin Drug Saf 2003;2:287-304.
60. Lewis JH, Zimmerman HJ. Drug- and chemical-induced cholestasis. Clin Liver Dis 1999;3:433-464, vii.
61. Desmet VJ. Vanishing bile duct syndrome in drug-induced liver disease. J Hepatol 1997;26(Suppl 1):31-35.
62. Degott C, Feldmann G, Larrey D, Durand-Schneider AM, Grange D, Macheyokhi JT, et al. Drug-induced prolonged cholestasis in adults: a histological semiquantitative study demonstrating progressive ductopenia. HEPATOLOGY 1992;15:244-251.
63. Trauner M, PJ Meier, JL Boyer, Molecular pathogenesis of cholestasis. N Engl J Med 1998;339:1217-1227.
64. Meier PJ, Stieger B. Molecular Mechanisms in Bile Formation. News Physiol Sci 2000;15:89-93.
65. Bohan A, Boyer JL. Mechanisms of hepatic transport of drugs: implications for cholestatic drug reactions. Semin Liver Dis 2002;22:123-136.
66. Kadmon M, Klunemann, Bohme C, Ishikawa M, Gorgas T, Otto K, et al. Inhibition by cyclosporin A of adenosine triphosphate-dependent transport from the hepatocyte into bile. Gastroenterology 1993;104:1507-1514.
67. Seitz S, Kretz-Rommel A, Oude Elferink RP, Boelsterli UA. Selective protein adduct formation of diclofenac glucuronide is critically dependent on the rat canalicular conjugate export pump (Mrp2). Chem Res Toxicol 1998;11:513-519.
68. Huang L, Smit JW, Meijer DK, Vore M. Mrp2 is essential for estradiol-17beta(beta-D-glucuronide)-induced cholestasis in rats. HEPATOLOGY 2000;32:66-72.
69. Fishbein M, Castro F, Cheruku S, Jain S, Webb B, Gleason T, et al. Hepatic MRI for fat quantitation: its relationship to fat morphology, diagnosis, and ultrasound. J Clin Gastroenterol 2005;39:619-625.
70. Fromenty B, Pessayre D. Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity. Pharmacol Ther 1995;67:101-154.
71. Letteron P, Sutton A, Mansouri A, Fromenty B, Pessayre D. Inhibition of microsomal triglyceride transfer protein: another mechanism for drug-induced steatosis in mice. HEPATOLOGY 2003;38:133-140.
72. Lewis W, Dalakas MC. Mitochondrial toxicity of antiviral drugs. Nat Med 1995;1:417422.
73. Mansouri A, Demeilliers C, Amsellem S, Pessayre D, Fromenty B. Acute ethanol administration oxidatively damages and depletes mitochondrial dna in mouse liver, brain, heart, and skeletal muscles: protective effects of antioxidants. J Pharmacol Exp Ther 2001;298:737-743.
74. Berson A, De Beco V, Letteron P, Robin A, Moreau C, El Kahwaji J, et al. Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. Gastroenterology 1998;114:764-774.
75. DeLeve LD, Shulman HM, McDonald GB. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis 2002;22:27-42.
76. Lamé MW, Jones AD, Wilson DW, Dunston SK, Segall HJ. Protein targets of monocrotaline pyrrole in pulmonary artery endothelial cells. J Biol Chem 2000;275:29091-29099.
77. DeLeve LD, Wang X, Tsai J, Kanel GC, Strasberg SM, Tokes ZA. Prevention of sinusoidal obstruction syndrome (hepatic venoocclusive disease) in the rat by matrix metalloproteinase inhibitors. Gastroenterology 2003;125:882-890.
78. DeLeve LD, Ito I, Bethea NW, McCuskey MK, Wang X, McCuskey RS. Embolization by sinusoidal lining cell obstructs the microcirculation in rat sinusoidal obstruction syndrome. Am J Physiol Gastro Liver Physiol 2003;284:G1045-G1052.
79. Eberhardt W, Beeg T, Beck KF, Walpen S, Gauer S, Bohles H, et al. Nitric oxide modulates expression of matrix metalloproteinase-9 in rat mesangial cells. Kidney Int 2000;57:59-69.
80. Upchurch GR Jr, Ford JW, Weiss SJ, Knipp BS, Peterson DA, Thompson RW, et al. Nitric oxide inhibition increases matrix metalloproteinase-9 expression by rat aortic smooth muscle cells in vitro. J Vasc Surg 2001;34:76-83.
81. DeLeve LD, Wang X, Kanel GC, Ito Y, Bethea NW, McCuskey MK, et al. Decreased hepatic nitric oxide production contributes to the development of rat sinusoidal obstruction syndrome. HEPATOLOGY 2003;38:900-908.
82. Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, Lewis KW. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 1994;271:992-998.
83. Torti VR, CobbA J, Everitt JI, Marshall MW, Boorman GA, Butterworth BE. Nephrotoxicity and hepatotoxicity induced by inhaled bromodichloromethane in wild-type and p53-heterozygous mice. Toxicol Sci 2001;64:269-280.
84. Shayiq RM, Roberts DW, Rothstein K, Snawder JE, Benson W, Ma X, et al. Repeat exposure to incremental doses of acetaminophen provides protection against acetaminophen-induced lethality in mice: an explanation for high acetaminophen dosage in humans without hepatic injury. HEPATOLOGY 1999;29:451-463.
85. Aleksunes LM, Slitt AM, Cherrington NJ, Thibodeau MS, Klaassen CD, Manautou JE. Differential expression of mouse hepatic transporter genes in response to acetaminophen and carbon tetrachloride. Toxicol Sci 2005;83:44-52.
86. Siewert E, Dietrich CG, Lammert F, Heinrich PC, Matern S, Gartung C, et al. Interleukin-6 regulates hepatic transporters during acute-phase response. Biochem Biophys Res Commun 2004;322:232-238.
87. Roberts E, Ahluwalia MB, Lee G, Chan C, Sarma DS, Farber E, et al. Resistance to hepatotoxins acquired by hepatocytes during liver regeneration. Cancer Res 1983;43:28-34.
88. Nunez M, Soriano V. Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. Drug Saf 2005;28:53-66.
89. Ogedegbe AO, Sulkowski MS. Antiretroviral-associated liver injury. Clin Liver Dis 2003;7:475-499.
90. Puoti M, Torti C, Ripamonti D, Castelli F, Zaltron S, Zanini B, et al. Severe hepatotoxicity during combination antiretroviral treatment: incidence, liver histology, and outcome. J Acquir Immune Defic Syndr 2003;32:259-267.
91. Lewis W, Day BJ, Copeland WC. Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective. Nat Rev Drug Discov 2003;2:812-822.
92. Lindon JC, Holmes E, Nicholson JK. Metabonomics: systems biology in pharmaceutical research and development. Curr Opin Mol Ther 2004;6:265-272.
93. Lindon JC, Holmes E, Nicholson JK. Metabonomics and its role in drug development and disease diagnosis. Expert Rev Mol Diagn 2004;4:189-199.
94. Nicholson JK, Nicholson JK, Connelly J, Lindon JC, Holmes E. Metabonomics: a platform for studying drug toxicity and gene function. Nat Rev Drug Discov 2002;1:153-1561.
95. Lindon JC, Keun HC, Ebbels TM, Pearce JM, Holmes E, Nicholson JK. The Consortium for Metabonomic Toxicology (COMET): aims, activities and achievements. Pharmacogenomics 2005;6:691-699.
96. Nicholls AW, Mortishire-Smith RJ, Nicholson JK. NMR spectroscopic-based metabonomic studies of urinary metabolite variation in acclimatizing germ-free rats. Chem Res Toxicol 2003;16:1395-1404.
97. Nicholson JK, Holmes E, Wilson ID. Gut microorganisms, mammalian metabolism and personalized health care. Nat Rev Microbiol 2005;3:431-438.
98. Torr-Brown S. Advances in knowledge management for pharmaceutical research and development. Curr Opin Drug Discov Devel 2005;8:316-322.
99. Bissell DM, Gores GJ, Laskin DL, Hoofnagle JH. Drug-induced liver injury: mechanisms and test systems. HEPATOLOGY 2001;33:1009-1013.
100. Maria VA, Victorino RM. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. HEPATOLOGY 1997;26:664-669.
101. Lucena MI, Camargo R, Andrade RJ, Perez-Sanchez CJ, Sanchez De La Cuesta F. Comparison of two clinical scales for causality assessment in hepatotoxicity. HEPATOLOGY 2001;33:123-130.
102. Aithal GP, Rawlins MD, Day CP. Clinical diagnostic scale: a useful tool in the evaluation of suspected hepatotoxic adverse drug reactions. J Hepatol 2000;33:949-952.
103. Macedo AF, Marques FB, Ribeiro CF, Teixeira F. Causality assessment of adverse drug reactions: comparison of the results obtained from published decisional algorithms and from the evaluations of an expert panel, according to different levels of imputability. J Clin Pharm Ther 2003;28:137-143.
104. Goodman ZD. Drug hepatotoxicity. Clin Liver Dis 2002;6:381-397.
105. Zimmerman H. The Adverse Effects of Drugs and Other Chemicals on the Liver. New York: Appleton-Century-Crofts, 1978.
106. Kleiner DE, Gaffey MJ, Sallie R, Tsokos M, Nichols L, McKenzie R, et al. Histopathologic changes associated with fialuridine hepatotoxicity. Mod Pathol 1997;10:192-199.
107. Heinloth AN, Irwin RD, Boorman GA, Nettesheim P, Fannin RD, Sieber S, et al. Gene expression profiling of rat livers reveals indicators of potential adverse effects. Toxicol Sci 2004;80:193-202.
108. Ruepp S, Boess F, Suter L, de Vera MC, Steiner G, Steele T, et al. Albertini, S. Assessment of hepatotoxic liabilities by transcript profiling. Toxicol Appl Pharmacol 2005;207(2 Suppl):161-170.
109. Raucy JL, Ingelman-Sundberg M, Carpenter S, Rannug A, Rane A, Franklin M, et al. Drug metabolizing enzymes in lymphocytes. J Biochem Mol Toxicol 1999;13:223-226.